Skip to main content
. Author manuscript; available in PMC: 2015 Jun 10.
Published in final edited form as: Clin Chim Acta. 2014 Mar 22;433:157–168. doi: 10.1016/j.cca.2014.03.016

Table 2.

Within-run precision of antiretroviral agent signal intensity and retention time.

High ARV control mixture Low ARV control mixture High and Low ng/ml ARV control mixture
Analyte Mean Signal Intensity (NL) (n=5) SD %CV Mean Signal Intensity (NL) (n=5) SD %CV Retention Time (min) (n=10) SD %CV
Protease Inhibitors
Amprenavir 6124463 183537 3.0 542972 26390 4.9 7.67 5.3E-03 0.07
Atazanavir 45121330 1625272 3.6 4192407 125739 3.0 8.56 5.7E-03 0.07
Darunavir 596270 57653 9.7 55117 7994 14.5 7.67 5.3E-03 0.07
Indinavir 28150923 1947717 6.9 2541560 310821 12.2 9.16 9.3E-02 1.01
Lopinavir 4612419 347425 7.5 358328 36614 10.2 8.89 1.3E-02 0.14
Nelfinavir 24949052 3455300 13.8 1139909 129655 11.4 10.40 8.3E-02 0.80
Ritonavir 13136967 1013771 7.7 1330593 113751 8.5 8.73 2.1E-02 0.24
Saquinavir 11302342 1382993 12.2 414473 77056 18.6 10.74 8.1E-02 0.76
Tipranavir 2114155 123453 5.8 127775 28046 21.9 9.66 1.3E-02 0.13
Nucleotide/Nucleoside Reverse Transcriptase Inhibitors
Emtricitabine 395381 11898 3.0 50474 1767 3.5 3.38 1.9E-02 0.57
Lamivudine 240402 10299 4.3 3020 291 9.6 1.98 2.3E-02 1.18
Tenofovir 27743 2107 7.6 1111 71 6.4 2.42 6.4E-02 2.64
Zidovudine 36033 4599 12.8 4055 1117 27.5 5.53 5.2E-03 0.09
Non-nucleoside Reverse Transcriptase Inhibitors
Efavirenz 7274 1497 20.6 12422 1472 11.9 8.57 3.1E-02 0.37
Nevirapine 5964711 355374 6.0 1467214 69109 4.7 5.54 1.0E-02 0.19